WVE Stock Price Target: What Analysts Expect for Wave Life Sciences
Wave Life Sciences (NASDAQ: WVE) has attracted growing attention from biotech investors as the company advances multiple RNA-based drug programs in obesity, alpha-1 antitrypsin deficiency (AATD), and liver disease. With WVE shares trading well below many Wall Street price targets, investors are asking an obvious question: How high do analysts think WVE stock could go? As of September 2026, analyst estimates vary significantly depending on the data provider. Some consensus calculations put the average WVE stock price target below $20, while others place it above $22. That wide range tells investors something important: Wall Street sees substantial potential in Wave Life Sciences, but there is also considerable uncertainty surrounding a clinical-stage biotech company. Quick Take Recent analyst aggregations show average 12-month WVE price targets ranging from roughly $17.60 to $22.31 , depending on the analysts and time periods included. Individual published targets s...